Guggenheim analyst Michael Schmidt initiated coverage of Mersana Therapeutics with a Buy rating and $14 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRSN:
- Mersana Plummets on Clinical Hold on Ovarian Cancer Trials
- Mersana Therapeutics Announces Partial Clinical Hold on UP-NEXT and UPGRADE-A Clinical Trials
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Mersana Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results